	US 11,865,146 B2
	Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection
Purna C. Kashyap, Rochester, MN (US); Eric J. Battaglioli, Rochester, MN (US); and Vanessa L. Hale, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Nov. 9, 2020, as Appl. No. 17/093,154.
Application 17/093,154 is a continuation of application No. 15/762,203, abandoned, previously published as PCT/US2016/053073, filed on Sep. 22, 2016.
Claims priority of provisional application 62/222,034, filed on Sep. 22, 2015.
Prior Publication US 2021/0128644 A1, May 6, 2021
Int. Cl. A61K 35/741 (2015.01); A61K 35/745 (2015.01); A61K 35/744 (2015.01); A61K 35/742 (2015.01); A61K 35/00 (2006.01); G01N 33/68 (2006.01); G01N 33/569 (2006.01); C12Q 1/04 (2006.01); A61P 31/04 (2006.01)

CPC A61K 35/741 (2013.01) [A61K 35/742 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61P 31/04 (2018.01); C12Q 1/04 (2013.01); G01N 33/56911 (2013.01); G01N 33/68 (2013.01); A61K 2035/115 (2013.01); G01N 2800/06 (2013.01); G01N 2800/26 (2013.01); Y02A 50/30 (2018.01)]

18 Claims

1. A method for treating Clostridium difficile infection in a mammal, the method comprising:

administering a composition comprising at least three bacteria selected from the group consisting of Roseburia, Faecalibacterium, Akkermansia, Blautia, and Bacteroides to a mammal identified as having an increased level of at least one free amino acid, wherein the at least one free amino acid is selected from the group consisting of proline, alanine, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, threonine, tryptophan, tyrosine, and valine,

wherein said composition restores a heathy gut microbiota in said mammal.